Overview

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is the first study to test Sym015 in humans. The primary purpose of this study is to see if Sym015 is safe and effective for patients with advanced solid tumor malignancies without available therapeutic options.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Symphogen A/S
Treatments:
Antibodies
Antibodies, Monoclonal